Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study
Galle, Jan-Christoph × Addison, Janet Suranyi, Michael G Claes, Kathleen Di Giulio, Salvatore Guerin, Alain Herlitz, Hans Kiss, István Farouk, Mourad Manamley, Nick Wirnsberger, Gerhard Winearls, Christopher #
Nephrology, Dialysis, Transplantation vol:Ahead of print
Extended dosing of the erythropoiesis-stimulating agent (ESA) darbepoetin alfa (DA) once biweekly or monthly reduces anaemia treatment burden. This observational study assessed outcomes and dosing patterns in patients with chronic kidney disease not on dialysis (CKD-NoD) commencing extended dosing of DA.